GlassScriptPhysician profile
Shakaib M Razzaq
NPI 1497712574
$1,913.52
in general payments reported to CMS, 2019-2025
27 companies · $683 in 2025
The $683 reported for 2025 was more than what 88% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.99 · 2020: $81.05 · 2021: $334 · 2022: $108 · 2023: $248 · 2024: $406 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $508.49 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $318.27 | 2021-2025 | |
| Daiichi Sankyo INC. | $142.86 | 2021-2022 | |
| Novo Nordisk INC | $99.43 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $94.27 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $66.91 | 2022-2025 | |
| Dexcom, INC. | $65.68 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $63.33 | 2025 | Voquezna |
| Amgen INC. | $63.11 | 2021-2024 | Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $60.55 | 2023-2025 | Gvoke Hypopen |
| Lundbeck LLC | $45.60 | 2024-2025 | Rexulti |
| Ardelyx, INC. | $43.73 | 2024-2025 | Ibsrela |
| Exact Sciences Corporation | $40.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Nestle Healthcare Nutrition INC. | $33.86 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $30.00 | 2025 | Purified Cortrophin Gel |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $28.02 | 2025 | Ocrevus Zunovo |
| Eisai INC. | $27.37 | 2022 | |
| Pfizer INC. | $26.90 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.58 | 2021 | |
| Aimmune Therapeutics, INC. | $20.22 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $19.20 | 2025 | Rexulti |
| Grifols USA, LLC | $18.99 | 2020 | |
| Cranial Technologies, INC | $17.06 | 2025 | Doc Band |
| Qol Medical, LLC | $16.08 | 2021 | |
| Merck Sharp & Dohme LLC | $13.24 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.83 | 2019 | |
| Therapeuticsmd, INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shakaib Razzaq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.